Ownership Summary
InMed Pharmaceuticals Inc. (NASDAQ:INM) has 7 institutional investors with active 13F positions as of December 2025.
- Collectively, these holders controlled 5.7% of InMed Pharmaceuticals's outstanding shares in December 2025, down from 7.7% in September 2025.
- They increased total shares held in InMed Pharmaceuticals by 3.06% from last quarter, and the number of investors in INM increased 16.67% annually.
- Among the 7 funds, 3 bought more InMed Pharmaceuticals shares, 1 sold down, and 3 held their ground.
- The aggregate institutional position in InMed Pharmaceuticals amounted to 227.05K shares as of December 2025, up by 6.74K shares quarter on quarter, and up 178.15K shares year over year.
- As of December 31, 2025, SABBY MANAGEMENT, LLC held the largest stake in InMed Pharmaceuticals with 201.63K shares, accounting for 5.1% of total shares outstanding.
- Leading buyers of InMed Pharmaceuticals shares for the quarter ending December 2025 were SUSQUEHANNA INTERNATIONAL GROUP, LLP (12.75K), JANE STREET GROUP, LLC (11.98K), UBS Group AG (377).
- Top sellers of INM stock for the quarter ending December 2025 included SABBY MANAGEMENT, LLC (18.37K).
- Per Business Quant data, the top 7 holders of InMed Pharmaceuticals for the quarter ending December 2025 are SABBY MANAGEMENT, LLC (201.63K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (12.75K), JANE STREET GROUP, LLC (11.98K), UBS Group AG (377), SBI Securities Co., Ltd. (300), Banque Cantonale Vaudoise (6), Federation des caisses Desjardins du Quebec (1).